Daiichi Sankyo has been listed on the 2019 DJSI World for the third consecutive year and DJSI Asia Pacific for the tenth consecutive year.

The Company was recognized for its strong performance in the areas of Marketing Practice, Corporate Citizenship and Philanthropy, Health Outcome Contribution and Strategy to Improve Access to Drugs.

Daiichi Sankyo will continue to make every effort to realize our corporate mission, "To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs," while fulfilling our social responsibility by performing activities that appropriately respond to sustainability challenges as we aim to continuously enhance corporate value.